Alnylam Pharmaceuticals
ALNY
Market cap $34.7B

268.46 USD

-2.56

0.94%

At close Mar 28, 4:00 PM EDT

After hours

266.52

-1.94

0.72%

1 day

-0.94%

5 days

-6.96%

1 month

8.80%

3 months

13.75%

6 months

-2.39%

Year to date

14.91%

1 year

79.63%

5 years

146.68%

10 years

149.08%

About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Employees: 2,230

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 7,390 funds

0

Analysts bullish %

of 12 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

55% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 60

31% more repeat investments, than reductions

Existing positions increased: 232 | Existing positions reduced: 177

17% more call options, than puts

Call options by funds: $195M | Put options by funds: $166M

4% more funds holding

Funds holding: 556 [Q3] → 577 (+21) [Q4]

2.72% more ownership

Funds ownership: 96.23% [Q3] → 98.95% (+2.72%) [Q4]

12% less capital invested

Capital invested by funds: $34B [Q3] → $30B (-$3.95B) [Q4]

43% less funds holding in top 10

Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]

See Fund Rankings

Research analyst outlook

12 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$284

6%

upside

Avg. target

$339

26%

upside

High target

$500

86%

upside

12 analyst ratings

10 positive

83%

2 neutral

17%

0 negative

0%

JP Morgan Jessica Fye 67% 1-year accuracy 26 / 39 met price target	22%upside $328	Overweight Upgraded	24 Mar 2025
Citigroup David Lebovitz 75% 1-year accuracy 12 / 16 met price target	31%upside $351	Buy Maintained	21 Mar 2025
Canaccord Genuity Whitney Ijem 28% 1-year accuracy 12 / 43 met price target	45%upside $390	Buy Maintained	21 Mar 2025
RBC Capital Luca Issi 29% 1-year accuracy 16 / 55 met price target	23%upside $330	Outperform Maintained	21 Mar 2025
Scotiabank Greg Harrison 49% 1-year accuracy 19 / 39 met price target	26%upside $338	Sector Outperform Maintained	21 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 15 articles about ALNY published over the past 30 days

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois.

Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.

FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering.

siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran).

Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock

Zacks Investment Research

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside.

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Zacks Investment Research

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy

Investors Business Daily

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra. The post Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio appeared first on Investor's Business Daily.

Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran) in adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.

Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps

Alnylam shares rise on expanded heart drug approval

Alnylam Pharmaceuticals' shares rose about 7% before the bell on Friday following U.S. approval for its drug for a rare and deadly heart disease, securing an entry into a market dominated by Pfizer's blockbuster Vyndaqel.

Alnylam shares rise on expanded heart drug approval

See News Rankings

Charts implemented using Lightweight Charts™